Format

Send to

Choose Destination
Circulation. 2019 Jan 15;139(3):410-412. doi: 10.1161/CIRCULATIONAHA.118.034993.

Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial.

Author information

1
Health Policy, Quality & Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research and Development Center for Innovations, Houston, TX (S.S.V., J.M.A.., L.A.P.).
2
Section of Health Services Research (S.S.V., J.M.A.., L.A.P.), Department of Medicine, Baylor College of Medicine, Houston, TX.
3
Section of Cardiovascular Research (S.S.V., V.N., C.M.B.), Department of Medicine, Baylor College of Medicine, Houston, TX.
4
Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX (S.S.V., V.N.).
5
Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX (S.S.V., V.N., C.M.B.).
6
Ciccarone Center for Prevention of Heart Disease, Johns Hopkins University, Baltimore, MD (E.D.M.).
7
Medical University of South Carolina, Charleston (P.B.M.).
8
Center for Healthcare Advancement & Outcomes at Baptist Health South Florida, Miami (K.N.).
9
Division of Cardiology, McAllister Heart Institute, University of North Carolina at Chapel Hill (S.C.S.).
10
Northwestern University Feinberg School of Medicine, Chicago, IL (N.J.S.).

KEYWORDS:

cholesterol; clinical trial

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center